Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany.
Praxisklinik für Hämatologie und Onkologie, Koblenz, Germany.
Support Care Cancer. 2019 Nov;27(11):4265-4271. doi: 10.1007/s00520-019-04721-4. Epub 2019 Mar 11.
Immunomodulatory drugs (IMIDS) have changed the treatment and outcome of patients suffering from multiple myeloma. However, with the oral administration adherence becomes an issue. Since there is no "gold standard" in measuring adherence, we assessed the adherence of myeloma patients with the help of different data sources.
All patients who have been receiving IMIDS for at least 3 months were eligible. Computer assisted personal interviews of patients and, if possible, their caregivers were carried out. Attending oncologists evaluated the patient's adherence with the help of a standardized questionnaire. In addition, a retrospective analysis of prescription data was conducted. All data were analyzed statistically using SPSS.
One hundred myeloma patients, 35% female, 65% male, with a median age of 70 years (37-86) were interviewed. Prescription data could be evaluated in terms of adherence in 78 patients (78%), 56 caregivers could be questioned (56%). Ninety-seven percent of patients rated themselves as adherent in taking IMIDS. Data from treating oncologists, caregivers and prescriptions supported this result. IMID therapies were rated as very effective and significant, toxicities were acceptable and dosing regimens simple/uncomplicated.
Myeloma patients seem to be highly adherent to IMID treatments.
免疫调节药物（IMIDs）改变了多发性骨髓瘤患者的治疗和预后。然而，由于口服药物的依从性成为一个问题。由于没有衡量依从性的“金标准”，我们借助不同的数据源评估骨髓瘤患者的依从性。
所有至少接受 IMIDs 治疗 3 个月的患者均符合条件。对患者及其护理人员（如果可能）进行计算机辅助的个人访谈。主治肿瘤医生借助标准化问卷评估患者的依从性。此外，还对处方数据进行了回顾性分析。所有数据均使用 SPSS 进行统计学分析。
对 100 名骨髓瘤患者（35%为女性，65%为男性）进行了访谈，他们的中位年龄为 70 岁（37-86 岁）。在 78 名患者（78%）中可以评估处方数据的依从性，56 名护理人员可以被问到（56%）。97%的患者自我评估对 IMIDs 的服用依从性较高。来自治疗肿瘤医生、护理人员和处方的数据支持了这一结果。IMID 治疗被评为非常有效和显著，毒性可接受，剂量方案简单/不复杂。
骨髓瘤患者对 IMID 治疗的依从性似乎很高。
